The Clinical Research E-News

Size: px
Start display at page:

Download "The Clinical Research E-News"

Transcription

1 Volume 2: ISSUE 6: March 24, 2010 The Clinical Research E-News SPECIAL ALERT: The annual JOG investigator Meeting will be held at 5pm on May 10, 2010 at the Loews Hotel. Now Open: AZ1071, A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis E1208, A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion. NCCTG/NO577, Phase III Intergroup Study of Radiotherapy versus Temozolomide alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma RTOG 0539, Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas. RTOG 0631, Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis.

2 Coming soon: NSABP FC-6, A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mfolfox7 Plus Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer with Metastases Confined to the Liver E2508, A Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients with (Bevacizumab-eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC) E3903, Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders. GOG258, A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma RTOG0627, Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma Multiforme, will be opened to the JKCCN only RTOG0831, A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated with Radiotherapy for Prostate Cancer. SWOG0521, A Randomized Trial of Maintenance Versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III. If your site is interested in participating in any of these studies please contact Rolma Gano at or Rolma.gano@jeffersonhospital.org.

3 Regulatory Update: The following studies have had recent consent form changes or updated letters posted on the repository website: RTOG 0813 ECOG 1208 CALGB90401 CALGB90601 ECOG2805 RTOG0848 RTOG0538/CALGB30610 If any of these studies pertain to your site please visit the repository at: Please contact Rolma Gano with any repository or other regulatory related questions. Quality Assurance Update: Please continue to check your online calendars for forms due and outstanding queries, in order to ensure timely data submission and query resolution. Data management tools can be found via NSABP's Coordinator Online system, ECOG's Expectancy and edcf systems, RTOG's Site Tools, and the CTSU Clinical Data website feature. Please contact Kelly Shipman with any QA related issues at or CTSU Update: The following protocols are coming soon to the OPEN system: E3508 and ACOSOG-Z1071. Please see the OPEN tab on the CTSU Members web site for more information about the protocols in OPEN. If you have a CTSU related question please contact Joshua Schoppe at or Joshua.schoppe@jeffersonhospital.org.

4 ECOG Update: ECOG Tissue Consent Survey: The ECOG Patient Representative Committee is asking for your help. An issue that has become very important to cancer clinical research is when, if ever, is it appropriate to mandate in our trials patient consent for immediate use or banking of pathologic specimens. To help us understand how ECOG members feel about mandating tissue consent in our trials, ECOG has developed a survey that takes only a few minutes of your time, and could provide us with very valuable insights into this complex issue. Please help ECOG by providing your input via this survey. It can be completed on the web at ECOG Performance Monitoring: The next Performance Monitoring data cut-off date of 3/31/2010 is approaching. Any data received on or before 3/31/2010 will be included in the upcoming Performance Monitoring. Data received after 3/31/2010 will be considered late. It is important to remember that data timeliness will be evaluated by assessing two components: The rate of CRF submitted and the rate of survival follow-up. To avoid penalties, each evaluable ECOG institution must have a score of 90% or better on each component. ECOG Spring Meeting: The ECOG spring meeting will be held at the JW Marriott Hotel in Washington, D.C., June 11 th through the 13 th. Meeting registration will be done online again for this meeting. To register for the Group Meeting, please use the link below. Please note that the schedule is updated on an ongoing basis. The schedule provided is for current reference only and is subject to change at any time. ECOG strongly recommends that all meeting attendees check the most current schedule online before making travel arrangements, as ECOG will not be responsible for ticket change fees due to scheduling changes.

5 If you have an ECOG related question please contact Joshua Schoppe. NSABP Update: NSABP Group Meeting: Registration is now open for the NSABP Group Meeting in San Francisco scheduled for April The registration link below is not posted on the NSABP website. Registration deadline has passed but it may still be possible to register. A tentative meeting schedule has been posted on the registration website. NSABP P-5, Statin Polyp Prevention Trial in Patients with Resected Colon Cancer, was activated on March 11, This is a phase III interventional trial for patients with resected stage I or II colon cancer. Stratification factors are family history of a first degree relative with colorectal cancer, intended aspirin dose (zero vs. 81mg vs. 325mg) and adjuvant therapy for colon cancer. Randomization is to placebo tablet daily x 5 years vs. rosuvastatin 10mg tablet once daily x 5 years. The primary aim is to determine if the administration of 5 years of postoperative rosuvastatin affects 5 year occurrence of adenomatous polyps of the colon or rectum, metachronous colorectal carcinoma and colon cancer recurrence in patients with resected colon cancer. The accrual goal is 1,740. Major eligibility criteria include surgical resection completed within 1 year before randomization and adjuvant therapy, if given, completed before randomization. Patients with hereditary colon cancer syndromes are excluded. See the NSABP Website for the complete protocol. Please mark your calendar for the NSABP audit scheduled for June 21, The chart of any JKCCN NSABP patient accrued in the last 3 years may be selected for audit. We will be notified of the announced charts on May 24, 2010.

6 If you have an NSABP related question please contact Vicki Squire at or at RTOG Update: The next RTOG Semiannual meeting will be held June 17-20, 2010, at the Loews Philadelphia Hotel in Philadelphia, PA. General information about the meeting can be found at Please preregister via the following link: Trial spotlight: Recently, the manuscript for RTOG 0236 was published in JAMA. This trial found that highly-focused stereotactic body radiation therapy (SBRT) can eliminate the targeted tumor while avoiding treatment-related illness and may ultimately improve survival for patients with inoperable nonsmall cell lung cancer. Stereotactic body radiation therapy (SBRT) is a noninvasive cancer treatment in which numerous small, highly focused, and accurate radiation beams are used to deliver potent doses in 1 to 5 treatments to tumor targets. Patients on this trial who received SBRT had a survival rate of 55% at 3 years, high rates of local tumor control, and moderate treatmentrelated morbidity. The complete manuscript can be found at If you have an RTOG related question please contact Kelly Shipman. Jefferson Oncology Group (JOG) Update: If your site has any JOG inquires please contact either Josh Schoppe or Vicki Squire. Jefferson Kimmel Cancer Center Network Homepage: This page contains links to the Remote Access Portal as well as the clinical trial document repository.

7 Upcoming Events: Oral Cancer Screening Event, TJU: April 14, 2010 NSABP Group Meeting, San Francisco: April JOG Investigator Meeting, Philadelphia: May 10 ECOG Spring Meeting, Washington, D.C.: June RTOG Semiannual Meeting, Philadelphia, PA: June The Clinical Research E-News Archive is now located on the Kimmel Cancer Center webpage under the JKCCN Member Area: Please provide feedback and any suggestions to Joshua Schoppe at or

The Clinical Research E-News

The Clinical Research E-News Volume 2: ISSUE 5: March 10, 2010 The Clinical Research E-News Coming soon: AZ1071, A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative

More information

The Clinical Research E-News

The Clinical Research E-News Volume 2: ISSUE 7: April 7, 2010 The Clinical Research E-News SPECIAL ALERT: The annual JOG investigator Meeting will be held at 5pm on May 10, 2010 at the Loews Hotel. Now Open: RTOG0831, A Randomized,

More information

The Clinical Research E-News

The Clinical Research E-News Volume 2: ISSUE 8: April 21, 2010 The Clinical Research E-News SPECIAL ALERT: The annual JOG investigator Meeting will be held at 5:30pm on May 10, 2010 at the Loews Hotel. Coming soon: NSABP FC-6, A Phase

More information

The Clinical Research E-News

The Clinical Research E-News Volume 2: ISSUE 10: May 19, 2010 The Clinical Research E-News Coming soon: NSABP FC-6, A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mfolfox7 Plus Cetuximab

More information

The Clinical Research E-News

The Clinical Research E-News Volume 2: ISSUE 11: June 2, 2010 The Clinical Research E-News SPECIAL ALERT: The quarterly CRA Meeting will be held at 8:30am on June 16, 2010 at the Bluemle Science Building room 105. Now Open: SWOG0777,

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 8: May 5, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: E2906, Phase III randomized

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 9: May 18, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: RTOG 0837, A Randomized,

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 2: ISSUE 19: October 13, 2010 Coming soon: RTOG 0929, A Randomized, Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant)

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 11: June 15, 2011 The Clinical Research E-News Reminder: CRA Quarterly Meeting, Philadelphia, PA: 10-11am on Wednesday June 22nd- Virtual Meeting: dial information attached in a separate

More information

The Clinical Research E-News

The Clinical Research E-News ISSUE 18: September 9, 2009 New Activations: The Clinical Research E-News SWOG0518, Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 2: ISSUE 23: December 16, 2010 Coming soon: E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma E2208, Randomized Phase II Study

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 3: February 16, 2011 The Clinical Research E-News Now Open: RTOG 0631, Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis RTOG 1010, A Phase III Trial Evaluating

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 5: March 23, 2011 The Clinical Research E-News Now Open: CALGB 90802, Randomized Phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 3: ISSUE 16: September 28, 2011 Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: C70604, A Randomized,

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 2: January 26, 2011 The Clinical Research E-News Now Open: E2208, Randomized Phase II Study of Paclitaxel With or Without the Anti- IGF-IR mab Cixutumumab (IMC-A12) as Second Line Treatment

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 4: March 2, 2011 The Clinical Research E-News Now Open: E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma E2208, Randomized Phase II Study of

More information

The Clinical Research E-News

The Clinical Research E-News ISSUE 10: May 20, 2009 The Clinical Research E-News New Activations at TJU: No new activations. Regulatory Update: The following studies have had recent consent form changes posted on the repository website:

More information

The Clinical Research E-News

The Clinical Research E-News Volume 4: ISSUE 6: August 28, 2012 The Clinical Research E-News Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Trials Opened at

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 6: ISSUE 5: June 12, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 7: ISSUE 1: January 16, 2015 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials

More information

Jefferson Kimmel Cancer Center Network Presents: The Clinical Research E-News. January 14, 2009

Jefferson Kimmel Cancer Center Network Presents: The Clinical Research E-News. January 14, 2009 Jefferson Kimmel Cancer Center Network Presents: January 14, 2009 The Clinical Research E-News New Activations at TJU: NCCTG N0723: A Phase III Biomarker Validation Study of Second-Line Therapy in Patients

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 6: ISSUE 5: May 14, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 7: ISSUE 2: February 19, 2015 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 6: ISSUE 11: November 19, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured JOG Trial

More information

SKCN E-Newsletter Volume 9 ISSUE 9 Regional Network Office

SKCN E-Newsletter Volume 9 ISSUE 9 Regional Network Office SKCN E-Newsletter Volume 9 ISSUE 9 Regional Network Office Clinical Trials at your Fingertips The Jefferson Clinical Trials app allows you to quickly reference the TJU clinical trials database, including

More information

National Cancer Institute Clinical Trial Cooperative Groups

National Cancer Institute Clinical Trial Cooperative Groups National Cancer Institute Clinical Trial Cooperative Groups Perspectives from the National Surgical Adjuvant Breast and Bowel Project Joyce Mull, MPM Director, Regulatory Affairs NSABP Foundation, Inc.

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including

More information

The Clinical Research E-News Volume 8: ISSUE 7: July 29, 2016

The Clinical Research E-News Volume 8: ISSUE 7: July 29, 2016 The Clinical Research E-News Volume 8: ISSUE 7: July 29, 2016 The Thomas Jefferson Sidney Kimmel Cancer Network (SKCN) would like to welcome our newest cancer network members, Kennedy Health System and

More information

SKCN E-Newsletter Volume 10 ISSUE 5 Regional Network Office

SKCN E-Newsletter Volume 10 ISSUE 5 Regional Network Office SKCN E-Newsletter Volume 10 ISSUE 5 Regional Network Office Clinical Trials at your Fingertips The Jefferson Clinical Trials app allows you to quickly reference the TJU clinical trials database, including

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and

More information

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study PNH Registry M07-001 DRUG CO NCT01374360 Blood Disorders-Other PNH Registry A071102 ALLIANCE NCT02152982

More information

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG

More information

National Cancer Policy Forum Workshop on Multi-Center Phase 3 Clinical Trials and NCI Cooperative Groups

National Cancer Policy Forum Workshop on Multi-Center Phase 3 Clinical Trials and NCI Cooperative Groups National Cancer Policy Forum Workshop on Multi-Center Phase 3 Clinical Trials and NCI Cooperative Groups Session 3: Data Collection Standards to Establish Safety and Efficacy: How Much Data Is Enough?

More information

Neuro-Oncology Program

Neuro-Oncology Program Neuro-Oncology Program The goals of the Neuro-oncology Committee are: 1) to improve duration and quality of life of brain tumor patients; 2) to assess disease and treatment-related effects on neurocognitive

More information

Research Strategy Committee Mitch Machtay, MD Deputy Group Chair, NRG RSC. NRG Semi-Annual Meeting Sunday, February 9, 2014

Research Strategy Committee Mitch Machtay, MD Deputy Group Chair, NRG RSC. NRG Semi-Annual Meeting Sunday, February 9, 2014 Research Strategy Committee Mitch Machtay, MD Deputy Group Chair, NRG RSC NRG Semi-Annual Meeting Sunday, February 9, 2014 The size of the Federal budget is not an appropriate barometer of social conscience

More information

THE TARGET. News from the Department of Radiation Oncology

THE TARGET. News from the Department of Radiation Oncology U T S O U T H W E S T E R N THE TARGET News from the Department of Radiation Oncology VOLUME 3, Spring 2012 Hippocampus-sparing trial of whole brain radiation seeks to preserve memory Beam arrangement

More information

The RPC s Evaluation of Advanced Technologies. AAPM Refresher Course July 29, 2008 Geoffrey S. Ibbott, Ph.D. and RPC Staff

The RPC s Evaluation of Advanced Technologies. AAPM Refresher Course July 29, 2008 Geoffrey S. Ibbott, Ph.D. and RPC Staff The RPC s Evaluation of Advanced Technologies AAPM Refresher Course July 29, 2008 Geoffrey S. Ibbott, Ph.D. and RPC Staff 1 http://rpc.mdanderson.org Supported by: NCI grants CA10953 and CA81647, and an

More information

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study A221101 ALLIANCE NCT01781468 Brain A Phase III Randomized, Double-Blind Placebo Controlled Study of

More information

ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD

ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD 7-12-12 ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy

More information

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tumor_treatment_fields_therapy 9/2013 11/2017 11/2018 6/2018 Description of Procedure or Service Tumor-treatment

More information

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved

More information

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND

More information

Page 1, column 2, entry for Lech Papiez: Line 2: Former was added in front of Medical Lines 4-7 of his entry were deleted.

Page 1, column 2, entry for Lech Papiez: Line 2: Former was added in front of Medical Lines 4-7 of his entry were deleted. For Amendment 7 to: RTOG 0813, Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Patients NCI/Local Protocol #: RTOG-0813/RTOG 0813 NCI Protocol Version Date: June 8, 2015 (Broadcast

More information

ACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD

ACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy Govindan, M.D. Carolyn Reed, MD

More information

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List A031501 ALLIANCE NCT03244384 Bladder Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR) Versus Observation NHLBI-MDS

More information

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG

More information

SHORE HEALTH SYSTEM INSTITUTIONAL REVIEW BOARD MHE Boardroom April 10, 2012

SHORE HEALTH SYSTEM INSTITUTIONAL REVIEW BOARD MHE Boardroom April 10, 2012 SHORE HEALTH SYSTEM INSTITUTIONAL REVIEW BOARD MHE Boardroom April 10, 2012 10 IRB members 6 or more = a quorum ATTENDANCE Chairman: Robert Cattaneo, JD - non-scientist Joan Banks non-scientist Kim Billingslea,

More information

EASTERN COOPERATIVE ONCOLOGY GROUP

EASTERN COOPERATIVE ONCOLOGY GROUP EASTERN COOPERATIVE ONCOLOGY GROUP E5204 INTERGROUP RANDOMIZED PHASE III STUDY OF POSTOPERATIVE OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN VS OXALIPLATIN, 5-FLUOROURACIL, LEUCOV- ORIN AND BEVACIZUMAB FOR

More information

CLINICAL TRIALS ACC. Jul 2016

CLINICAL TRIALS ACC. Jul 2016 CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

More information

NSABP B-55/BIG Lynne Suhayda, RN, MSEd. Director, Clinical Coordinating Department. NRG Oncology - Pittsburgh, Pennsylvania

NSABP B-55/BIG Lynne Suhayda, RN, MSEd. Director, Clinical Coordinating Department. NRG Oncology - Pittsburgh, Pennsylvania NSABP B-55/BIG 6-13 Lynne Suhayda, RN, MSEd. Director, Clinical Coordinating Department NRG Oncology - Pittsburgh, Pennsylvania NRG Oncology Meeting July 15, 2016 Lynne Suhayda, RN, MSEd. No Financial

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process Quality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Appropriate Use of Healthcare 2019 COLLECTION TYPE:

More information

Erbitux. Erbitux (cetuximab) Description

Erbitux. Erbitux (cetuximab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)

More information

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,

More information

Cancer Endorsement Maintenance 2011-Maintenance Measures

Cancer Endorsement Maintenance 2011-Maintenance Measures Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212

More information

Quality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care

Quality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care Quality ID #264: Sentinel Lymph de Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process

More information

ELECTRIC TUMOR TREATMENT FIELDS

ELECTRIC TUMOR TREATMENT FIELDS ELECTRIC TUMOR TREATMENT FIELDS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices

More information

Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support

Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no

More information

Navigating Alliance Protocols

Navigating Alliance Protocols Navigating Alliance Protocols Morgen Alexander-Young, MPH Alliance Central Protocol Operations Program Alliance Spring 2017 Group Meeting Alliance Protocol History Alliance for Clinical Trials in Oncology

More information

Welcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar

Welcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar American College of Surgeons Clinical Research Program Kelly K. Hunt, M.D. Program Director Welcome to American College of Surgeons Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar Moderator:

More information

What Can Go Wrong in Radiation Treatment: Data from the RPC. Geoffrey S. Ibbott, Ph.D. and RPC Staff

What Can Go Wrong in Radiation Treatment: Data from the RPC. Geoffrey S. Ibbott, Ph.D. and RPC Staff What Can Go Wrong in Radiation Treatment: Data from the RPC Geoffrey S. Ibbott, Ph.D. and RPC Staff Clinical NCI Trials CALGB 1768 Participating Institutions NCCTG ECOG COG ACOSOG SWOG QARC RPC ATC RTOG

More information

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED

More information

Heterogeneity of N2 disease

Heterogeneity of N2 disease Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity

More information

Session II: Academic Research in Breast Cancer: Challenges and Opportunities Robert L. Comis, MD ECOG-ACRIN Group Co-Chair

Session II: Academic Research in Breast Cancer: Challenges and Opportunities Robert L. Comis, MD ECOG-ACRIN Group Co-Chair Session II: Academic Research in Breast Cancer: Challenges and Opportunities Robert L. Comis, MD ECOG-ACRIN Group Co-Chair Symposium: Innovation in Breast Cancer 2014 Madrid, Spain February 21, 2014 Cancer

More information

Clinical Trials OPEN to ENROLLMENT

Clinical Trials OPEN to ENROLLMENT CNS 2014 Second Quarter Clinical Trials OPEN to ENROLLMENT GAB 101 (CNS THERAPEUTICS INC): Safety of 3 mg/ml Gablofen (baclofen injection) Delivered by Intrathecal Administration Using the Synchromed II

More information

Radiation Oncology MOC Study Guide

Radiation Oncology MOC Study Guide Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.

More information

CancerPACT Cancer Patients Alliance for Clinical Trials

CancerPACT Cancer Patients Alliance for Clinical Trials TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal

More information

NRG Publications Committee. Chair: Deborah Watkins Bruner, PhD Co-chairs: Elizabeth Gore, MD Thomas Julian, MD Krish Tewari, MD

NRG Publications Committee. Chair: Deborah Watkins Bruner, PhD Co-chairs: Elizabeth Gore, MD Thomas Julian, MD Krish Tewari, MD NRG Publications Committee Chair: Deborah Watkins Bruner, PhD Co-chairs: Elizabeth Gore, MD Thomas Julian, MD Krish Tewari, MD NRG Abstract and Manuscript Submissions 161 Manuscripts 105 Publications in

More information

Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer

Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California

More information

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design: Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA

More information

Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy

Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a

More information

Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer

Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer - Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

Critical Clinical Updates

Critical Clinical Updates Critical Clinical Updates ASTRO Spring Refresher Course JW Marriott Hotel Ramesh Rengan MD PhD Department of Radiation Oncology Friday March 22, 2013 Learning Objectives At the conclusion of this activity,

More information

Eligibility Form. 1. Patient Profile. (This form must be completed before the first dose is dispensed.) Request prior approval for enrolment

Eligibility Form. 1. Patient Profile. (This form must be completed before the first dose is dispensed.) Request prior approval for enrolment Bevacizumab in combination with Paclitaxel and Carboplatin - Frontline Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (This form must be completed before the first

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

THORACIC MALIGNANCIES

THORACIC MALIGNANCIES THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,

More information

Results of the ACOSOG Z0011 Trial

Results of the ACOSOG Z0011 Trial DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD, Mary J. Mackenzie, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED

More information

MULTI-GROUP AUDITS, THE CENTRAL MONITORING PORTAL, AND OTHER CTSU UPDATES

MULTI-GROUP AUDITS, THE CENTRAL MONITORING PORTAL, AND OTHER CTSU UPDATES MULTI-GROUP AUDITS, THE CENTRAL MONITORING PORTAL, AND OTHER CTSU UPDATES OISHI SYMPOSIUM 10/11/2017 1 Agenda Multi-Group Audits Central Monitoring Portal Website and Administrative Updates 10/11/2017

More information

Adjuvant Chemotherapy for Rectal Cancer: Are we making progress?

Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones

More information

The Clinical Research E-News Volume 7: ISSUE 11: November 20, 2015

The Clinical Research E-News Volume 7: ISSUE 11: November 20, 2015 The Clinical Research E-News Volume 7: ISSUE 11: November 20, 2015 Congratulations to Drs. Maria Werner-Wasik, Russell Schilder and Scott Goldstein for leading Thomas Jefferson University in recognition

More information

Sentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD

Sentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD Sentinel Node Biopsy Is There Any Role for Axillary Dissection? JCCNB Nov 20, 2010 Tokyo, Japan Stephen B. Edge, MD Roswell Park Cancer Institute University at Buffalo Buffalo, NY USA SNB with Clinically

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED

More information

Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer This is a two-arm, randomized phase II trial for patients with BRAF mutant

More information

Breast Cancer Clinical Trials in Georgia

Breast Cancer Clinical Trials in Georgia www.georgiacore.org www.georgiatrials.org Breast Clinical Trials in Georgia Breast in Georgia: The Facts As the leading cause of cancer incidence among Georgia females, breast cancer accounts for 32 percent

More information

THE TARGET. New radiation oncology facility showcases latest technology. News from the Department of Radiation Oncology.

THE TARGET. New radiation oncology facility showcases latest technology. News from the Department of Radiation Oncology. U T S O U T H W E S T E R N THE TARGET News from the Department of Radiation Oncology VOLUME 2, WINTER 2011 2012 New radiation oncology facility showcases latest technology Harold C. Simmons Comprehensive

More information

Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology. 20 Combination Treatments for Glioblastoma

Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology. 20 Combination Treatments for Glioblastoma BRAIN CANCER 18 Brain Cancer Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Henry S. Friedman, MD Duke University Medical Center Durham, North Carolina 20

More information

Corporate Medical Policy Tumor-Treatment Fields Therapy for Glioblastoma

Corporate Medical Policy Tumor-Treatment Fields Therapy for Glioblastoma Corporate Medical Policy Tumor-Treatment Fields Therapy for Glioblastoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tumor-treatment_fields_therapy_for_glioblastoma 9/2013 11/2017

More information

Current Status and Future Medical Perspectives at MedAustron. U. Mock EBG MedAustron GmbH

Current Status and Future Medical Perspectives at MedAustron. U. Mock EBG MedAustron GmbH Current Status and Future Medical Perspectives at MedAustron U. Mock EBG MedAustron GmbH Cancer treatment facility Ion beam therapy with protons and carbon ions Research facility Medical physics Radiobiology

More information

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles 2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla

More information

General Information. Please silence cell phones. Locations Restrooms to the left of the ballroom, or to your right by the elevators

General Information. Please silence cell phones. Locations Restrooms to the left of the ballroom, or to your right by the elevators American American College College of of Surgeons 2013 Content 2014 Content cannot be be reproduced or or repurposed without written permission of of the the American College College of Surgeons. of Surgeons.

More information

Best of ASTRO 2016 Czech Republic

Best of ASTRO 2016 Czech Republic Best of ASTRO 2016 Czech Republic 20. 3. 2017 Kongresové centrum Kunětická Hora Dříteč 09:30-10:10 Track 1 - Gastrointestinal Renata Soumarova, Ass. Prof. (Oncology Centre Novy Jicin, Agel) Abstract 1:

More information

PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France

PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative

More information

For Protocol Amendment 3 of: NRG-BR001, A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

For Protocol Amendment 3 of: NRG-BR001, A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases For Protocol Amendment 3 of: NRG-BR001, A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases NCI/Local Protocol #: NRG-BR001/NRG BR001 NCI Protocol Version

More information

6/23/2010. Publicly Funded Clinical Trials in the Era of Comparative Effectiveness Research. Goals of Therapeutic Clinical Trials

6/23/2010. Publicly Funded Clinical Trials in the Era of Comparative Effectiveness Research. Goals of Therapeutic Clinical Trials Publicly Funded Clinical Trials in the Era of Comparative Effectiveness Research Richard L. Schilsky, M.D. Professor and Chief Section of Hematology-Oncology University of Chicago Deputy Director, Comprehensive

More information

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Project Overview Ronald C. Chen, MD MPH Introductions Principal Investigator: Ronald C. Chen, MD MPH ACS Staff: Eileen Tonner,

More information

Thierry M. Muanza, MSc, MD, FRCPC,, McGill University Segal Cancer Centre, Jewish General Hospital Montreal, QC, Canada

Thierry M. Muanza, MSc, MD, FRCPC,, McGill University Segal Cancer Centre, Jewish General Hospital Montreal, QC, Canada Thierry M. Muanza, MSc, MD, FRCPC,, McGill University Segal Cancer Centre, Jewish General Hospital Montreal, QC, Canada Déclarations Aucun conflit d intérêt Objectifs d apprentissage Évolution de la radiothérapie

More information